METASTATIC BREAST CARCINOMA

This early-stage trial aims to find the safest and most effective dose of two drugs—cyclophosphamide and veliparib—when given together. It is for people with advanced breast cancer that has spread and is HER2-negative. The main goal is to understand the side effects and determine…

This study is testing whether adding an immunotherapy drug (pembrolizumab) to two standard breast cancer medications improves outcomes for postmenopausal women whose estrogen-driven breast cancer has spread. The goal is to see if this three-drug combination can shrink tumors and …

This large, late-stage trial is testing whether adding a new drug called entinostat to standard hormone therapy (exemestane) works better than the hormone therapy alone. It's for people whose hormone-sensitive, advanced breast cancer has continued to grow despite prior treatment.…

This study is testing whether adding an immunotherapy drug (atezolizumab) to a targeted cancer drug (olaparib) works better than the targeted drug alone for people with advanced breast cancer that has a specific genetic flaw (BRCA mutation). The goal is to see if the combination …

This early-stage trial is testing the safety of a new combination treatment for people with advanced cancers that have spread and cannot be removed by surgery. Doctors inject immune-stimulating drugs directly into a tumor, then give a small dose of radiation to that same spot. Th…

This study is testing if adding a new drug called copanlisib to the standard two-drug treatment (fulvestrant and abemaciclib) is more effective for advanced breast cancer that has stopped responding to hormone therapy. It will involve about 24 patients with hormone-positive, HER2…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This early-stage trial is testing a combination of two drugs, niraparib and dostarlimab, for people with advanced breast, ovarian, pancreatic, or related cancers that have a specific genetic change (BRCA mutation) and have stopped responding to standard treatments. The goal is to…

This study is testing whether a special type of PET/CT scan can better measure how well treatment is working for breast cancer that has spread to the bones. About 138 patients with this type of advanced cancer will get the scan before starting treatment and again 12 weeks later. …

This clinical trial is testing whether a substance called GM1 can prevent or reduce nerve damage caused by a common chemotherapy drug, paclitaxel. The study involves about 100 people with metastatic breast cancer who are scheduled to receive paclitaxel treatment. Participants are…

This study aims to see if doctors can reliably measure the amount of a common chemotherapy drug, paclitaxel, in a patient's blood. The goal is to learn if tracking these drug levels can help doctors adjust doses to better fight cancer while reducing a major side effect: nerve dam…

This study aims to collect tissue samples, blood, and medical information from 300 patients with advanced breast cancer that has spread. Researchers will analyze these samples to understand why breast cancer spreads to other parts of the body and why different patients respond di…

This study is testing whether a short educational video can help patients with advanced cancer better understand tumor genomic testing. It involves 243 adults with metastatic breast or lung cancer who are already scheduled for this type of testing. Researchers will measure if wat…